Prof Allan Hackshaw

Photo

Personal Profile

Name: Allan Hackshaw Email: a.hackshaw@ucl.ac.uk
Title: Prof Tel: 0044 207 679 9893
Department: CRUK Cancer Trials Centre Fax: 0044 207 679 9899
Position: Professor of Epidemiology and Medical Statistics Address: 90 Tottenham Court Road, London, London, W1T 4TJ
Research Domain: Cancer, Personalised Medicine Web Page: Personal Web Page

Profile

Research Description

- Design, analysis and conduct of clinical trials and epidemiological studies, mainly in cancer. - Systematic reviews and meta-analyses - Medical screening (all areas, particularly for cancer and antenatal disorders) - Tobacco and health (the effects of active and passive smoking)

Research Activities

Clinical trials and epidemiological studies

Education Description

"Understanding statistical concepts in clinical research" - PhD and M.Sc students in UCL Biomedicine "Clinical trials": M.Sc Students in UCL Statistics Dept "Medical screening" - City University

UCL Collaborators

External Collaborators

Publications

    2013

    • Teh M-T, Hutchison IL, Costea DE, Neppelberg E, Liavaag PG, Purdie K, Harwood C, Wan H, Odell EW, Hackshaw A, Waseem A (2013). Exploiting FOXM1-orchestrated molecular network for early squamous cell carcinoma diagnosis and prognosis. International Journal of Cancer, 132(9), 2095 - 2106. doi:10.1002/ijc.27886
    • Kadalayil L, Benini R, Pallan L, O'Beirne J, Marelli L, Yu D, Hackshaw AK, Fox R, Johnson P, Burroughs AK, Palmer DH, Meyer T (2013). A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Annals of Oncology, , - . doi:10.1093/annonc/mdt247
    • Hackshaw A, Kadalayil L, Mallick U (2013). Well-Being after Radiation Therapy in Thyroid Cancer. New England Journal of Medicine, 368(7), 685 - 686. doi:10.1056/NEJMc1212592
    • Hackshaw AK, Leonardi-Bee J (2013). Epidemiology of the association between smoking and mental disorders. In (Ed.), Smoking and mental health. A report by the Tobacco Advisory Group of the Royal College of Physicians (pp. 63 - 83). : Royal College of Physicians.
    • McCormack M, Kadalayil L, Hackshaw AK, Hall-Craggs MA, Symonds RP, Warwick V, Simonds H, Fernando I, Hammond M, James L, Feeney A, Ledermann JA (2013). A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. British Journal of Cancer, 108(12), 2464 - 2469.

    2012

    • Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn J, John R, Nutting C, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A (2012). Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer. New England Journal of Medicine, 366, 1674 - 1685.
    • Patel D, Akporobaro A, Chinyanganya N, Hackshaw A, Seale C, Spiro SG, Griffiths C, Investigators L-S (2012). Attitudes to participation in a lung cancer screening trial: a qualitative study. THORAX, 67(5), 418 - 425. doi:10.1136/thoraxjnl-2011-200055
    • Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Chao D, Middleton G, Bulley S, Ngai Y, Rudd R, Hackshaw A, Boshoff C (2012). First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.. Lancet Oncol, 13(11), 1161 - 1170. doi:10.1016/S1470-2045(12)70412-6
    • Jitlal M, Khan I, Lee SM, Hackshaw AK (2012). Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies. British Journal of Cancer, 107, 910 - 917.
    • (2012). Review of mammographic screening.
    • Hackshaw A (2012). Benefits and harms of mammography screening. BMJ, 344(jan06 1), d8279 - d8279. doi:10.1136/bmj.d8279
    • Hackshaw A (2012). The benefits and harms of mammographic screening for breast cancer: building the evidence base using service screening programmes. Journal of Medical Screening, 19(Supplement 1), 1 - 2. doi:10.1258/jms.2012.012074

    2011

    • Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, Earl H, Perren T, Gore M, Persic M, Adams M, James L, Temple G, Merger M, Rustin G (2011). Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.. J Clin Oncol, 29(28), 3798 - 3804. doi:10.1200/JCO.2010.33.5208
    • MacGregor A, Frith A, Hackshaw A (2011). Migraine and co-morbid depression: an open label study of eletriptan and sertraline. Journal of Clinical Psychopharmacology, 31(3), 392 - 393.
    • Marsh D, Suchak K, Moutasim KA, Vallath S, Hopper C, Jerjes W, Upile T, Kalavrezos N, Violette SM, Weinreb PH, Chester KA, Chana JS, Marshall JF, Hart IR, Hackshaw AK, Piper K, Thomas GJ (2011). Stromal features are predictive of disease mortality in oral cancer patients.. J Pathol, 223(4), 470 - 481. doi:10.1002/path.2830
    • Hackshaw A, Roughton M, Forsyth S, Monson K, Reczko K, Sainsbury R, Baum M (2011). Long-term benefits of 5 years of tamoxifen: 10 year follow up of a large randomised trial in women aged at least 50 years with early breast cancer. Journal of Clinical Oncology, 29(13), 1657 - 1663.
    • Hackshaw A, Kirkwood A (2011). Interpreting and reporting clinical trials with results of borderline significance. BMJ, 343(jul04 2), d3340 - d3340. doi:10.1136/bmj.d3340
    • Hackshaw A, Rodeck C, Boniface S (2011). Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls. Human Reproduction Update, 17(5), 589 - 604. doi:10.1093/humupd/dmr022

    2010

    • Hackshaw A (2010). How to Write a Grant Application.
    • Hackshaw A (2010). Tobacco and other disorders. In Strauss DL, Boyle P, Gray N, Henningfield J, Seffrin J, Zatonski W (Ed.), Tobacco; science, policy and public health (pp. 577 - 596). : Oxford Univ Pr.
    • Wheatley-Price P, Blackhall F, Lee SM, Ma C, Ashcroft L, Jitlal M, Qian W, Hackshaw A, Rudd R, Booton R, Danson S, Lorigan P, Thatcher N, Shepherd F (2010). The Influence of Sex and Histology on Outcomes in Non-Small Cell Lung Cancer: a Pooled Analysis of 5 Randomized Trials. Annals of Oncology, 21(10), 2023 - 2028.
    • Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C, Buscombe J, Grillo J, Mayer A, Hochhauser D, Begent RH, Caplin ME, Meyer T (2010). Chemotherapy with 5-Fluorouracil, Cisplatin and Streptozocin (FCiSt) for neuroendocrine tumors. British Journal of Cancer, 102(7), 1106 - 1112.
    • Hackshaw A, Leonardi-Bee J (2010). Effects of maternal active and passive smoking on fetal and reproductive health. In Britton J, Edwards R (Ed.), Passive smoking and children. A report by the Tobacco Advisory Group of the Royal College of Physicians (pp. 40 - 76). : Royal College of Physicians.

    2009

    • Hackshaw A (2009). The NCRI prospective randomised trial of high (standard) versus low dose 131I ablation with or without recombinant TSH (HiLo).. In Miles A (Ed.), The effective management of head, neck and thyroid cancer. UK Key Advances in Clinical Practice (pp. - ). : Aesculapius Medical Press.
    • Hackshaw A (2009). A concise guide to clinical trials. doi:10.1002/9781444311723
    • Tobias J, Monson K, Gupta N, MacDougall H, Glaholm J, Hutchison I, Kadalayil L, Hackshaw A (2009). Chemo-radiotherapy for locally advanced head and neck cancer: ten-year follow up of the UK Head and Neck (UKHAN1) trial. Lancet Oncology, 11, 66 - 74.
    • Hackshaw A (2009). Luteinizing hormone-releasing hormone (LHRH) agonists in the treatment of breast cancer. Expert Opinion on Pharmacotherapy, 10(16), 1 - 7.
    • Srirajaskanthan R, Dancey G, Hackshaw A, Luong T, V C, M M, T (2009). Circulating Angiopoietin-2 is elevated in NETs and correlates with disease burden and progression. Endocrine-Related Cancer, 16(3), 967 - 976.
    • McCormack M, Ledermann J, Hall-Craggs M, Symonds P, Warwick V, Fernando I, Hackshaw A (2009). Phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer.
    • Lee SM, Rudd R, Woll P, Ottensmeier C, Gilligan D, Price A, Gower N, Jitlal M, Hackshaw A (2009). Anti-angiogenic therapy using thalidomide, combined with chemotherapy, in small cell lung cancer: a randomized double-blind placebo-controlled trial. Journal of the National Cancer Institute, 101, 1049 - 1057.
    • Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Whelan J, Jürgens H (2009). Zwei randomisierte Ewing Sarkom Studien. Schweizer Krebsbulletin - Bulletin suisse du cancer (Swiss Cancer Bulletin), 29(2), 128 - 134.
    • Hackshaw A, Baum M, Fornander T, Nordenskjold B, Nicolucci A, Monson K, Forsyth S, Reczko K, Johansson U, Fohlin H, Valentini M, Sainsbury R (2009). Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer. Journal of the National Cancer Institute, 101(5), 341 - 349. doi:10.1093/jnci/djn498
    • Maniaci V, Davidson BR, Rolles K, Dhillon AP, Hackshaw A, Begent RH, Meyer T (2009). Fibrolamellar hepatocellular carcinoma - prolonged survival with multimodality therapy. European Journal of Surgical Oncology, 35(6), 617 - 621. doi:10.1016/j.ejso.2008.12.009
    • Lee SM, Rudd R, Woll PJ, Ottensmeier C, Gilligan D, Price A, Spiro S, Gower N, Jitlal M, Hackshaw A (2009). Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer.. J Clin Oncol, 27(31), 5248 - 5254. doi:10.1200/JCO.2009.21.9733
    • Hackshaw AK, Mallick U (2009). Low versus high I-131 dose for remnant ablation in differentiated thyroid cancer. Clinical Medicine and Research, 7(1/2), 1 - 3.

    2008

    • Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, Schuck A, Winkelmann W, Kohler G, Poremba C, Zoubek A, Ladenstein R, van den Berg H, Hunold A, Cassoni A, Spooner D, Grimer R, Whelan J, McTiernan A, Jurgens H (2008). Results of the EICESS-92 study: Two randomized trials of Ewing's sarcoma treatment - Cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J CLIN ONCOL, 26(27), 4385 - 4393. doi:10.1200/JCO.2008.16.5720
    • Hackshaw A (2008). Small studies: strengths and limitations. European Respiratory Journal, 32, 1141 - 1143.
    • Hackshaw A, Farrant H, Bulley S, Seckl M, Ledermann J (2008). Setting up non-commercial clinical trials takes too long in the UK: findings from a prospective study. Journal of the Royal Society of Medicine, 101, 299 - 304.
    • Mallick U, Harmer C, Hackshaw A (2008). The HiLo Trial: a Multicentre Randomised Trial of High- versus Low-dose Radioiodine, with or without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation after Surgery for Differentiated Thyroid cancer. Clinical Oncology, (20(5)), 325 - 326.
    • Paulussen M, Craft AW, Lewis I, Hackshaw A, Weston C, Douglas C, Ahrens S, Dunst J, Schuck A, Winkelmann W, Exner GH, Köhler G, Leuschner I, Poremba C, Zoubek A, Ladenstein R, van DBH, Hunold A, Cassoni A, Spooner D, Grimer R, Whelan J, McTiernan A, Jürgens H (2008). EICESS-92 – Results of two randomised trials of the European intergroup Cooperative Ewing's Sarcoma Study (The European Intergroup Cooperative Ewing's Sarcoma Study Group). Journal of Clinical Oncology, 26(27), 4385 - 4393.
    • Hackshaw AK (2008). Environmental tobacco smoke. In Everitt BS, Melnick EL (Ed.), Encyclopedia of Quantitative Risk Assessment (pp. - ). : John Wiley.
    • Lee SM, James L, Buchler T, Snee M, Ellis P, Hackshaw A (2008). Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. Lung Cancer, 59(3), 364 - 368. doi:10.1016/j.lungcan.2007.08.032

    2007

    • Hackshaw AK, Spiro SG (2007). The timing of radiotherapy when given with chemotherapy in patients with small-cell lung cancer. Am J Hematology/Oncology, 6(2), 74 - 78.
    • Underwood B, Hackshaw A, Fox K (2007). Smoking, alcohol and drug use among vocational dental practitioners in 2000 and 2005. British Dental Journal, 203(12), 701 - 705. doi:10.1038/bdj.2007.1112
    • Spiro SG, Hackshaw AK (2007). The role of radiotherapy in the first line treatment of small cell lung cancer. Minerva Pneumologica, 46(4), 287 - 296.
    • Wong A, Lovat L, Burnham RW, Hackshaw A, Fitzgerald R (2007). Large-scale prospective study reveals novel risk factors for Barrett's oesophagus.
    • Ngeh J, Hackshaw A, Gupta S (2007). The relationship between socioeconomic deprivation, atypical respiratory infections and survival outcome in elderly stroke and medical patients. Cerebrovascular Diseases, 24, 546 - 547. doi:10.1159/000111223
    • Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA (2007). I-131 activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review.. Journal of Clinical Endocrinology and Metabolism, 92(1), 28 - 38.
    • Lee SM, Woll PJ, Rudd RM, Gower NH, Ottensmeier CH, Ali K, Spiro S, Hackshaw A (2007). A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC).
    • Wong A, Lovat L, Burnham RW, Hackshaw A, Fitzgerald R (2007). Large-scale prospective study reveals novel risk factors for Barrett's oesophagus. Gastroenterology, 132(4), 254 - 255.
    • Hackshaw AK (2007). Risk profile of smoked tobacco. In Britton J, Edwards R (Ed.), Harm reduction in nicotine addiction: helping people who can’t quit. A report by the Tobacco Advisory Group of the Royal College of Physicians (pp. 104 - 118). : Royal College of Physicians.

    2006

    • Baum M, Hackshaw A, Houghton J, Rutqvist L, Fornander T, Nordenskjold B, Nicolucci A, Sainsbury R (2006). Adjuvant goserelin in premenopausal patients with early breast cancer: results from the ‘Zoladex’ in premenopausal patients (ZIPP) trial. European Journal of Cancer, 42, 895 - 904.
    • Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM, Bestwick JP (2006). First- and second-trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS) (vol 10, pg 56, 2003). J MED SCREEN, 13(1), 51 - 52.
    • Szlosarek PW, Fennell DA, Rudd RM, Lind M, Ranson M, Hackshaw A, Bomalaski JS, Steele JPC (2006). A randomized phase II trial of pegylated arginine deaminase (ADI-PEG 20) in patients with malignant pleural mesothelioma.
    • Hackshaw AK, Paul EA, Davenport E (2006). Evidence-based dentistry: an introduction.
    • Hackshaw A (2006). Smoke gets in your eyes – well only until mid-2007. Significance, 3(2), 63 - 65.
    • MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A (2006). Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology, 67(12), 2154 - 2158.
    • Spiro SG, James LJ, Rudd RM, Trask CW, Tobias JS, Snee M, Gilligan D, Murray PA, Ruiz DEM-C, KM OD, Gower NH, Harper PG, Hackshaw AK (2006). Early versus Late Radiotherapy as Combined Modality Treatment for Limited - Disease Small-Cell Lung Cancer : a London Lung Cancer Group Multi-centre Randomised Clinical Trial. Journal of Clinical Oncology, 24(24), 3823 - 3830. doi:10.1200/JCO.2005.05.3181
    • MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A (2006). Prevention of menstrual attacks of migraine - A double-blind placebo-controlled crossover study. Neurology, 67(12), 2159 - 2163.

    2005

    • Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Lambert-Messerlian G, Wald NJ, Rudnicka AR, Hackshaw AK, D Alton ME (2005). First-trimester or second-trimester screening, or both, for Down's syndrome.. New England Journal of Medicine, 353(19), 2001 - 2011. doi:10.1056/NEJMoa043693
    • Hackshaw AK (2005). Passive smoking; what is it and why is it harmful?. In Britton J, Edwards R (Ed.), Going smoke-free: the medical case for clean air in the home, at work and in public places. A report on passive smoking of the Tobacco Advisory Group of the Royal College of Physicians (pp. 1 - 11). : Royal College of Physicians.
    • Nebot M, López MJ, Gorini G, Neuberger M, Axelsson S, Pilali M, Fonseca C, Abdennbi K, Hackshaw A, Moshammer H, Laurent AM, Salles J, Georgouli M, Fondelli MC, Serrahima E, Centrich FAHSK (2005). Environmental tobacco smoke exposure in public places of European cities. Tobacco Control, 14, 60 - 63.
    • Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A (2005). The future of antenatal screening for Down's Syndrome - Reply. BJOG-INT J OBSTET GY, 112(1), - . doi:10.1111/j.1471-0528.2005.00475.x
    • Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A (2005). SURUSS in perspective. Seminars in Perinatology, 29(4), 225 - 235.
    • Hackshaw AK, Knight A, Barrett-Lee P, Leonard R (2005). Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. BRITISH JOURNAL OF CANCER, 93(11), 1215 - 1221. doi:10.1038/sj.bjc.6602858
    • Strachan D, Hackshaw AK (2005). Health effects of environmental tobacco smoke. In Britton J, Edwards R (Ed.), Going smoke-free: the medical case for clean air in the home, at work and in public places. A report on passive smoking of the Tobacco Advisory Group of the Royal College of Physicians (pp. 13 - 28). : Royal College of Physicians.

    2004

    • Wald N, Rodeck CH, Hackshaw A, Rudnicka A (2004). SURUSS in perspective. British Journal of Obstetrics and Gynaecology, 111, 521 - 531.
    • Wald N, Rodeck C, Rudnicka A, Hackshaw A (2004). Nuchal translucency and gestational age. Prenatal Diagnosis, 24, 150 - 153.
    • Wald NJ, Rodeck CR, Ruldnicka AR, Hackshaw AK (2004). Nuchal translucency and gestational age - Response to Nicolaides. PRENATAL DIAG, 24(10), 834 - 835. doi:10.1002/pd.1046
    • MacGregor A, Hackshaw A (2004). Prevalence of migraine on each day of the natural menstrual cycle. Neurology, 63, 351 - 353.
    • Hackshaw AK, Sweetenham J, Knight A (2004). Are hematopietic growth factors worthwhile in the management of previously untreated patients with high-grade non-Hodgkin’s lymphoma?. British Journal of Cancer, 90, 1302 - 1305.
    • Hackshaw A (2004). Tobacco Smoke and Involuntary Smoking (A Hackshaw member of expert working group).
    • Hackshaw AK (2004). Tobacco and other disorders. In Boyle P, Gray N, Henningfield J, Seffrin J, Zatonski W (Ed.), Tobacco: The Public Health Disaster of the Twentieth Century (pp. 593 - 619). : Oxford University Press.
    • Vineis P, Alavanja M, Buffler P, Fontham E, Francecshi S, Gao YT, Gupta PC, Hackshaw A, Matos E, Samet J, Sitas F, Smith J, Stayner L, Straif K, Thun MJ, Wichmann HE, Wu AH, Zaridze Z, Peto R, Doll R (2004). Tobacco and cancer: recent epidemiological evidence. Journal of the National Cancer Institute, 96(2), 99 - 106. doi:10.1093/jnci/djh014

    2003

    • Wald NJ, Rodeck C, Hackshaw AK, Walters JC, Chitty L, Mackinson AM (2003). First and second trimester antenatal screening for Down’s syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Journal of Medical Screening, 10(2), 56 - 104. doi:10.1258/096914103321824133
    • Wald NJ, Huttly WJ, Hackshaw AK (2003). Antenatal screening for Down's syndrome with the quadruple test.. Lancet, 361(9360), 835 - 836. doi:10.1016/S0140-6736(03)12680-3
    • Ward LK, Clarke R, Hackshaw AK (2003). Do food-plant preferences of modern families of phytophagous insects and mites reflect past evolution with plants?. Biological Journal of the Linnean Society, 78, 51 - 83.
    • Hackshaw AK (2003). The EUSOMA review on mammography screening. In: Proceedings from the Global Summit on Mammographic Screening, Milan 2002. Annals of Oncology, 14, 1193 - 1195.
    • Boyle P, Autier P, Bartelink H, Baselga J, Boffetta P, Burn J, Burns HJG, Christensen L, Denis L, Dicato M, Diehl V, Doll R, Franceschi S, Gillis CR, Gray N, Griciute L, Hackshaw A, Kasler M, Kogevinas M, Kvinnsland S, La Vecchia C, Levi F, McVie JG, Maisonneuve P, Martin-Moreno JM, Newton Bishop J, Oleari F, Perrion P, Quinn M, Richards M, Ringborg U, Scully C, Siracka E, Storm H, Tubiana M, Tursz T, Veronesi U, Wald N, Weber W, Zaridze DG, Zatonski W, zur Hausen H (2003). European code against cancer and scientific justification: third version (2003). Annals of Oncology, 14(7), 973 - 1005.
    • Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM (2003). First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technology Assessment, 7(11), 1 - 77. doi:10.3310/hta7110
    • Wald NJ, Rish S, Hackshaw AK (2003). Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies.. Prenat Diagn, 23(7), 588 - 592. doi:10.1002/pd.627
    • Geddes JF, Tasker RC, Hackshaw AK, Nickols CD, Adams GG, Whitwell HL, Scheimberg I (2003). Dural haemorrhage in non-traumatic infant deaths: does it explain the bleeding in ‘shaken baby syndrome’?. Neuropathology and Applied Neurobiology, 29, 14 - 22.
    • Hackshaw AK, Paul EA (2003). Breast-self examination and death from breast cancer: a meta-analysis. British Journal of Cancer, 88, 1047 - 1053.
    • Hackshaw A (2003). Paper does not diminish conclusion of previous reports. On behalf of the International Agency for Research on Cancer Working Group on Smoking and Involuntary smoking. BMJ (Clinical Research Ed.), 327, 501 - 502.

    2002

    • MacGregor A, Hackshaw A (2002). Prevention of migraine in the pill-free week of combined oral contraceptives using natural oestrogen supplements: A double-blind placebo controlled study. Journal of Family Planning and Reproductive Health Care, 28(1), 27 - 31.
    • Wald NJ, Hackshaw AK (2002). Folic acid supplementation and neural tube defects.. Am J Med Genet, 109(1), 79 - .
    • Hackshaw AK, Wald NJ (2002). Estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening. Prenatal Diagnosis, 22, 1051 - 1055.
    • Rudnicka AR, Wald NJ, Huttly W, Hackshaw AK (2002). Influence of maternal smoking on the birth prevalence of Down syndrome and on second trimester screening performance.. Prenat Diagn, 22(10), 893 - 897. doi:10.1002/pd.440
    • Wald NJ, Huttly W, Hackshaw AK (2002). Antenatal screening policies for Down's syndrome. Audit of Down's syndrome screening is not valid.. BMJ, 325(7371), 1034 - .

    2001

    • Hackshaw AK, Wald NJ (2001). Assessment of the value of reporting partial screening results in prenatal screening for Down syndrome. Prenatal Diagnosis, 21, 737 - 740.
    • Hackshaw AK, Wald NJ (2001). Inaccurate estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening. Prenatal Diagnosis, 21, 741 - 746.
    • Geddes JF, Hackshaw AK, Vowles GH, Nicoll JAR, Whitwell HL (2001). Neuropathology of inflicted head injury in children. I: Patterns of brain damage. Brain, 124, 1290 - 1298.
    • Hackshaw AK, Wald NJ, George LM (2001). Singleton versus duplicate assays in maternal serum screening - Reply. PRENATAL DIAG, 21(10), 895 - 896.
    • Wald NJ, Hackshaw AK (2001). Folic acid and miscarriage – an unjustified link. American Journal of Medical Genetics Part A, 98, 204 - .
    • Hackshaw AK, Wald NJ, George LM (2001). Measuring serum markers once or twice in each assay in antenatal screening for Down syndrome and neural tube defects. Prenatal Diagnosis, 21, 72 - 73.
    • Geddes JF, Vowles GH, Hackshaw AK, Scott IS, Whitwell HL (2001). Neuropathology of inflicted head injury in children. II: Microscopic brain injury in infants. Brain, 124, 1299 - 1306.
    • Hackshaw AK, Wald NJ (2001). Revised distribution parameters for serum markers for trisomy 18. Journal of Medical Screening, 7, 215 - 216.

    2000

    • Wald NJ, Hackshaw AK, George LM (2000). Assay precision of serum alphafetoprotein in antenatal screening for neural tube defects and Down's syndrome (vol 7, pg 74, 2000). J MED SCREEN, 7(3), 168 - 168.
    • Hackshaw AK, Law MR, Wald NJ (2000). Passive smoking and lung cancer: increased risk is not disputed. British Medical Journal, 321, 1221 - 1222.
    • Wald NJ, Hackshaw AK, Huttly W (2000). Screening for Down's syndrome. Serum screening programmes are effective and safe.. BMJ, 321(7263), 763 - 764.
    • Law MR, Hackshaw AK, Wald NJ (2000). Mammography screening for breast cancer. Lancet, 355, 749 - 750.
    • Wald NJ, Hackshaw AK, Cuckle HS (2000). Maternal serum alphafetoprotein screening for open neural tube defects: revised statistical parameters.. BJOG, 107(2), 296 - 298.
    • Wald NJ, Hackshaw AK (2000). Advances in antental screening for Down's syndrome. In Rodeck CH (Ed.), Bailliere's Best Practice & Research in Clinical Obstetrics & Gynaecology; Diagnosis of genetic defects in the fetus (pp. 563 - 580). : Bailliere Tindall, UK.
    • Wald NJ, Hackshaw AK (2000). Principles of screening II: Multiple tests. In Wald NJ, Leck I (Ed.), Antenatal and Neonatal Screening (pp. 23 - 57). : Oxford University Press.
    • Wald NJ, Hackshaw AK, Watt H (2000). Nuchal translucency and trisomy 18. Prenatal Diagnosis, 20, 353 - 354.
    • Hackshaw AK, Wald NJ, Field S, Michell M, Wilson R (2000). An investigation into why two-view mammography is better than one-view in breast cancer screening. Clinical Radiology, 55, 454 - 458.
    • Wald NJ, Hackshaw AK, George L (2000). Assay precision of serum alpha-fetoprotein in antenatal screening for neural tube defects and Down's syndrome. Journal of Medical Screening, 7, 74 - 77.
    • Hackshaw AK, Wald NJ (2000). Repeat testing in antenatal screening for Down's syndrome using dimeric inhibin-A in combination with other maternal serum markers. Prenatal Diagnosis, (21), 58 - 61.

    1999

    • Berkenstadt H, Rosenthal T, Segal E, Peleg E, Ben-Ari G, Perel A, Hackshaw A (1999). Elevated plasma atrial natriuretic peptide levels after occlusion of the thoracic aorta. Chest, 115(1), 130 - 134.
    • Hackshaw A, Wald NJ, Ayme A (1999). Statement from panel on antenatal screening for Down syndrome. In Beazoglou T, Benn P, Cuckle H, Haddow J, Kyriopoulos J (Ed.), Down syndrome: Screening policy and economic evaluations (pp. 261 - 265). : National School of Public Health, Exandus Publishers, Athens.
    • Wald NJ, Hackshaw AK (1999). Development and implementation of Down's syndrome screening. In Beazoglou T, Benn P, Cuckle H, Haddow J, Kyriopoulos J (Ed.), Down syndrome: Screening policy and economic evaluations (pp. 55 - 68). : National School of Public Health, Exandus Publishers, Athens.
    • Wald NJ, Hackshaw AK, Watt H (1999). Nuchal translucency and trisomy 18. Prenatal Diagnosis, 19, 995 - 996.
    • Mathews F, Murphy M, Wald N, Hackshaw A (1999). Twinning and folic acid use. The Lancet, 353, 291 - .
    • Wald NJ, Watt HC, Hackshaw AK (1999). Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. New England Journal of Medicine, 341, 461 - 467.
    • McLean M, Bisits A, Davis J, Walters W, Hackshaw A, de VK, Smith R (1999). Predicting risk of preterm delivery by second trimester measurement of maternal plasma corticotropin-releasing hormone and alpha-fetoprotein. American Journal of Obstetrics and Gynecology, 181(1), 207 - 215.
    • Wald NJ, Hackshaw AK, Frost C (1999). When can a risk factor be used as a worthwhile screening test?. BMJ (Clinical Research Ed.), 319, 1562 - 1565.
    • Wald NJ, Hackshaw AK, Diamandis EP, Melegos DN (1999). Maternal serum prostate specific antigen and Down's syndrome in the first and second trimesters of pregnancy. Prenatal Diagnosis, (19), 674 - 676.

    1998

    • Hackshaw A (1998). Lung cancer and passive smoking. Statistical Methods in Medical Research, 7(2), 119 - 136.
    • Wald NJ, Hackshaw AK (1998). Correct estimation of parameters for ultrasound nuchal translucency screening - Authors' reply. PRENATAL DIAG, 18(5), 521 - 523.
    • Wald NJ, Hackshaw AK (1998). Response to: Wald, N.J., Hackshaw, A.K. (1997). Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome, Prenat. Diagn., 17, 821-829. Authors' reply. PRENATAL DIAG, 18(5), 515 - 519.
    • Hackshaw AK, Law MR, Wald NJ (1998). Passive smoking and lung cancer - reply. BRIT MED J, 317(7154), 348 - 348.
    • Hackshaw AK, Densem J, Wald NJ (1998). Repeat maternal serum testing for Down's Syndrome screening using multiple markers with special reference to free alpha and free beta-hCG (vol 15, pg 1125, 1995). PRENATAL DIAG, 18(5), 525 - 526.
    • Law M, Hackshaw A (1998). Meta-analysis of cigarette smoking and bone mineral density and risk of hip fracture. British Medical Journal, 316, 1017 - .
    • Hackshaw AK, Wald NJ, Law M (1998). Passive smoking and lung cancer. British Medical Journal, 317, 346 - .
    • Hackshaw AK, Law MR, Wald NJ (1998). Nonsmokers exposed to other people's tobacco smoker have an increased risk for lung cancer. Evidence-Based Medicine, Jul/Aug, 126 - .
    • (1998). Antenatal screening for Down's syndrome. Health Technology Assessment, 2(1), 1 - 77.
    • Schuchter K, Wald NJ, Hackshaw AK, Hafner E, Liebhardt E (1998). The distribution of nuchal translucency at 10-13 weeks of gestation.. Prenatal Diagnosis, 18, 281 - 286.

    1997

    • Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG, Watt H, Hackshaw A, Morris JK (1997). Inhibin-A in Down's syndrome pregnancies: revised estimate of standard deviation. Prenatal Diagnosis, 17, 285 - 290.
    • Wald N, Hackshaw A (1997). Folic acid and prevention of neural tube defects. The Lancet, 350(9078), 665 - .
    • (1997). Antenatal screening for Down's syndrome. Journal of Medical Screening, 4, 181 - 246.
    • Hackshaw AK, Law MR, Wald NJ (1997). The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ (Clinical Research Ed.), 315, 980 - 988.
    • Wald NJ, Hackshaw AK (1997). Combining ultrasound and biochemistry in first trimester screening for Down's syndrome. Prenatal Diagnosis, 17(9), 821 - 829.
    • Law M, Hackshaw AK (1997). A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ (Clinical Research Ed.), 315, 841 - 846.
    • Wald NJ, Hackshaw AK (1997). Screening using risk estimation: uses and abuses of the method. In Grudzinskas JG, Ward RHT (Ed.), Screening for Down syndrome in the First Trimester (pp. 45 - 53). : Royal College of Obstetrics and Gynaecologists Press.
    • Law MR, Cheng R, Hackshaw AK, Allaway S, Hale AK (1997). Cigarette smoking, sex hormones and bone density in women.. Eur J Epidemiol, 13(5), 553 - 558.
    • Hackshaw AK (1997). Developments in antenatal screening for Down's syndrome. Reverberations. Journal of the United Kingdom Association of Sonographers, 1, 15 - 18.

    1996

    • Wald NJ, Hackshaw AK (1996). Cigarette smoking: an epidemiological overview. In Doll R, Crofton J (Ed.), Tobacco and Health (pp. 3 - 11). : .
    • Wald NJ, Hackshaw AK (1996). Risk estimation in Down's syndrome screening.. Prenat Diagn, 16(11), 1055 - 1057. doi:10.1002/(SICI)1097-0223(199611)16:11<1055::AID-PD990>3.0.CO;2-B
    • Wald NJ, Kennard A, Hackshaw AK (1996). First trimester serum screening for Down's syndrome (vol 15, pg 1227, 1995). PRENATAL DIAG, 16(4), 387 - 387.
    • Hackshaw AK (1996). Screening for breast cancer in young women using breast self-examination. In Hannaford PC, Webb AMC (Ed.), Evidence-Guided Prescribing of the Pill (pp. 217 - 226). : Parthenon Publishing Group.
    • Law MR, Hackshaw AK (1996). Environmental tobacco smoke. In Doll R, Crofton J (Ed.), Tobacco and Health (pp. 22 - 34). : .
    • Wald NJ, Hackshaw AK, Stone R, Sourial NA (1996). Blood folic acid and Vitamin B12 in relation to neural tube defects. British Journal of Obstetrics and Gynaecology, 103, 319 - 329.
    • Ward LK, Hackshaw A, Clarke RT (1996). Evidence of evolution of food-plant associations shown by families of phytophagous British insects and mites.
    • Wald NJ, Hackshaw AK, Huttly W, Kennard A (1996). Empirical validation of risk screening for Down's syndrome. Journal of Medical Screening, 3(4), 185 - 187.
    • Hackshaw AK, Wald NJ, Haddow JE (1996). Down's syndrome screening with nuchal translucency. The Lancet, 348, 1740 - .
    • Wald NJ, George L, Hackshaw A (1996). Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. British Journal of Obstetrics and Gynaecology, 103, 1174 - 1175.

    1995

    • Wald NJ, Kennard A, Hackshaw AK (1995). First trimester serum screening for Downs syndrome. Prenatal Diagnosis, 15, 1227 - 1240.
    • Hackshaw AK, Densem J, Wald NJ (1995). Repeat maternal serum testing for Downs syndrome screening using multiple markers with special reference to free alpha and free beta hCG. Prenatal Diagnosis, 15, 1125 - 1130.
    • Ward LK, Hackshaw A, Clarke RT (1995). Food-plant families of British insects and mites: the influence of life form and plant family. Biological Journal of the Linnean Society, 55(2), 109 - 127. doi:10.1111/j.1095-8312.1995.tb01054.x
    • Hackshaw AK, Kennard A, Wald NJ (1995). Detection of pregnancies with trisomy 18 in screening programmes for Downs syndrome. Journal of Medical Screening, 2, 228 - 229.

    1994

    • Wald NJ, Hackshaw AK, Chamberlain J (1994). The efficacy and safety of periodic mammographic breast cancer screening: summary of report of the European Society of Mastology. Clinical Radiology, 49(9), 592 - 593.
    • Wald N, Chamberlain J, Hackshaw A (1994). Societe Europeene de Mastologie: Conference de consensus sur le depistage du cancer du sein. Journal de Radiologie, 75, 303 - 312.
    • Wald N, Chamberlain J, Hackshaw A (1994). Consensus Conference on Breast Cancer Screening. Oncology, 51, 380 - 389.
    • Wald NJ, Chamberlain J, Hackshaw AK (1994). European Society of Mastology Consensus Conference on Breast Cancer screening. Clinical Oncology, 6(4), 261 - 268.
    • Wald NJ, Chamberlain J, Hackshaw AK (1994). European Society of Mastology. Consensus Conference on Breast Cancer Screening. Bulletin du Cancer, 81(10), 825 - 834.
    • Law MR, Wald NJ, Wu T, Hackshaw A (1994). Safety of cholesterol reduction remains in doubt. British Medical Journal, 308, 1105 - .
    • Law MR, Wald NJ, Wu T, Hackshaw AK, Bailey A (1994). Systematic underestimation of the association between serum cholesterol and ischaemic heart disease in observational studies: data from the BUPA Study. BMJ (Clinical Research Ed.), 308(6925), 363 - 366.
    • Wald NJ, Chamberlain J, Hackshaw AK (1994). European Society of Mastology Consensus Conference on Breast Cancer Screening: report of the evaluation committee. British Journal of Radiology, 67(802), 925 - 933.
    • Mattu RK, Needham EW, Morgan R, Rees A, Hackshaw AK, Stocks J, Elwood PC, Galton DJ (1994). DNA variants at the LPL gene locus associate with angiographically defined severity of atherosclerosis and serum lipoprotein in a Welsh population. Arteriosclerosis, Thrombosis, and Vascular Biology, 14(7), 1090 - 1097.

    1993

    • Hambidge M, Hackshaw AK, Wald NJ (1993). Neural tube defects and serum zinc. British Journal of Obstetrics and Gynaecology, 100(8), 746 - 749.
    • Wald NJ, Hackshaw AK, Haddow JE, Palomaki GE, Knight GJ (1993). Use of free beta-hCG in Downs syndrome screening. Annals of Clinical Biochemistry, 30(5), 512 - 513.
    • Wald NJ, Hackshaw AK (1993). Antenatal screening for Downs syndrome. British Medical Journal, 306(6886), 1198 - 1199.
    • Wald N, Chamberlain J, Hackshaw A (1993). Report of the European Society for Mastology Breast Cancer Screening Evaluation Committee. Tumori, 79, 371 - 379.
    • Wald NJ, Chamberlain J, Hackshaw AK (1993). Report of the European Society for Mastology Breast Cancer Screening Evaluation Committee. The Breast, 2, 209 - 216.
    • Wald NJ, Hackshaw AK, Stone R, Densem J (1993). Serum alpha-fetoprotein and neural tube defects in the first trimester of pregnancy. Prenatal Diagnosis, 13(11), 1047 - 1050.

    • Lee SM, Hackshaw A (). A potential new enriching trial design for selecting non-small-cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial. Cancer Medicine, 2(3), 360 - 366. doi:10.1002/cam4.74
    • Khan I, Sarker SJ, Hackshaw AK (). Smaller sample sizes for phase II trials based on exact tests with actual error rates by trading-off their nominal levels of significance and power. British Journal of Cancer, 107, 1801 - 1809.
    • Sweetenham J, Hackshaw A, Knight A (). Evidence-based review and meta-analysis of the use of hematopoietic growth factors (HGF’s) in the management of malignant lymphoma.
    • MacGregor EA, Hackshaw AK (). Prevalence of migraine on each day of the menstrual cycle in women not using hormonal treatments.
    • MacGregor EA, Hackshaw AK (). Prevalence of migraine on each day of the menstrual cycle in women not using hormonal treatments.
    • MacGregor EA, Hackshaw AK (). Prevalence of migraine on each day of the menstrual cycle.
    • Hackshaw A, Jitlal M, Kadalayil L (). Long-term follow up of clinical trials: is it worth it?.
    • Hackshaw AK (). The NCRI prospective randomised trial of high (standard) versus low dose 131I ablation with or without recombinant TSH (HiLo). In Miles A (Ed.), The effective management of head, neck and thyroid cancer (pp. - ). : Aesculapius Medical Press.
    • Hackshaw AK (). A concise guide to observational studies in health care.
    • Beasley R, Martinez FD, Hackshaw A, Rabe K, Sterk PJ, Djukanovic R (). Safety of long-acting beta-agonists: urgent need to clear the air remains. European Respiratory Journal, 33(1), 3 - 5.
    • Lee SM, Woll PJ, James LE, Hatton M, Ali K, Spiro SG, Ali S, Hackshaw A (). A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC).
    • Ledermann J, Rustin GJ, Hackshaw A, Kaye SB, Jayson G, Gabra H, James L, Bell S, Temple G (). A randomized placebo-controlled phase II trial to evaluate the angiogenesis inhibitor BIBF 1120 as maintenance therapy following chemotherapy of relapsed ovarian cancer (OC).
    • Mallick U, Harmer C, Clarke S, Moss L, Nicol A, Clarke P, Smellie J, McCready R, Farnell K, Franklyn J, John R, Nutting C, Yap B, Lemon C, Wadlsey J, Gerrard G, Roques T, Macias E, Whitaker S, Abdul-Hamid A, Alvarez P, Kadalayil L, Hackshaw A (). HiLo: Multicentre randomised phase III clinical trial of high vs low dose radioiodine, with or without recombinant human thyroid stimulating hormone (rhTSH), for remnant ablation for differentiated thyroid cancer.